Imbalance of tumor necrosis factor-α, interleukin-8 and interleukin-10 production evokes barrier dysfunction, severe abdominal symptoms and psychological disorders in patients with irritable bowel syndrome-associated diarrhea

Zhen,Yanbo; Chu,Chuanlian; Zhou,Shiqing; Qi,Ming; Shu,Ronghua

doi:10.3892/mmr.2015.4079

Imbalance of tumor necrosis factor-α, interleukin-8 and interleukin-10 production evokes barrier dysfunction, severe abdominal symptoms and psychological disorders in patients with irritable bowel syndrome-associated diarrhea

Authors:
- Yanbo Zhen
- Chuanlian Chu
- Shiqing Zhou
- Ming Qi
- Ronghua Shu
View Affiliations

Affiliations: Department of Gastroenterology, Jinan Central Hospital, Jinan, Shandong 250013, P.R. China
Published online on: July 15, 2015 https://doi.org/10.3892/mmr.2015.4079
Pages: 5239-5245

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to explore the correlation between cytokine expression of tumor necrosis factor α (TNF‑α), interleukin (IL)‑8 and IL‑10 with occludin production, abdominal symptoms and psychological factors in patients with irritable bowel syndrome‑associated diarrhea (IBS‑D). A total of 42 IBS‑D patients and 20 healthy controls were included, which were recruited from QiLu Hospital in China. ELISA and immunohistochemical analysis were performed for evaluating the cytokines (TNF‑α, IL‑8 and IL‑10) and occludin protein levels in the peripheral blood mononuclear cells (PBMCs) of all subjects. In addition, the abdominal symptoms and psychological status were assessed in IBS‑D patients. Levels of TNF‑α and IL‑8 in the PBMCs of patients with IBS‑D were significantly higher than those in the controls (P<0.001 and P=0.007, respectively), while IL‑10 levels were significantly reduced in patients with IBS‑D (P=0.047). Occludin production was significantly reduced in patients with IBS‑D as compared with that in the controls (P<0.001). In patients with IBS‑D, levels of TNF‑α and IL‑8 were negatively correlated with occludin levels (r=‑0.34, P=0.028; r=‑0.52, P<0.001, respectively). IL‑10 showed a negative correlation with occludin production (r=0.05, P=0.748). Furthermore, TNF‑α, IL‑8 and IL‑10 levels were significantly correlated with symptoms scores (r=0.74, P<0.001; r=0.55, P<0.001; r=‑0.80, P<0.001, respectively) in patients with IBS‑D. Within the IBS‑D group, TNF‑α expression was significantly increased in patients with a self‑rating depression scale (SDS) score ≥50 (P=0.004) as compared with that in patients with an SDS score <50. Furthermore, IL‑8 was significantly increased in IBS‑D patients with a self‑rating anxiety scale (SAS) or SDS score ≥50 (P=0.016, P=0.008, respectively) as compared with that in patients scoring <50. In conclusion, the results of the present study suggested that in IBS‑D, an imbalance of cytokine production evoked colonic epithelial barrier dysfunction, abdominal symptoms and psychological disorders.

View Figures

View References

1	Schmulson MW and Chang L: Diagnostic approach to the patient with irritable bowel syndrome. Am J Med. 107:20S–26S. 1999. View Article : Google Scholar : PubMed/NCBI
2	Holten KB, Wetherington A and Bankston L: Diagnosing the patient with abdominal pain and altered bowel habits: is it irritable bowel syndrome? Am Fam Physician. 67:2157–2164. 2003.PubMed/NCBI
3	Andresen V and Camilleri M: Irritable bowel syndrome: recent and novel therapeutic approaches. Drugs. 66:1073–1088. 2006. View Article : Google Scholar : PubMed/NCBI
4	van der Veek PP, van den Berg M, de Kroon YE, Verspaget HW and Masclee AA: Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol. 100:2510–2516. 2005. View Article : Google Scholar : PubMed/NCBI
5	Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ and Hutchinson IV: Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut. 52:91–93. 2003. View Article : Google Scholar
6	Nielsen OH, Rüdiger N, Gaustadnes M and Horn T: Intestinal interleukin-8 concentration and gene expression in inflammatory bowel disease. Scand J Gastroenterol. 32:1028–1034. 1997. View Article : Google Scholar : PubMed/NCBI
7	Coëffier M, Gloro R, Boukhettala N, et al: Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. Am J Gastroenterol. 105:1181–1188. 2010. View Article : Google Scholar
8	Simrén M, Abrahamsson H, Svedlund J and Björnsson E: Quality of life in patients with irritable bowel syndrome seen in referral centers versus primary care: the impact of gender and predominant bowel pattern. Scand J Gastroenterol. 36:545–552. 2001. View Article : Google Scholar : PubMed/NCBI
9	Piche T, Huet PM, Gelsi E, et al: Fatigue in irritable bowel syndrome: characterization and putative role of leptin. Eur J Gastroenterol Hepatol. 19:237–243. 2007. View Article : Google Scholar : PubMed/NCBI
10	Piche T, Saint-Paul MC, Dainese R, et al: Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut. 57:468–473. 2008. View Article : Google Scholar : PubMed/NCBI
11	Drossman DA and Dumitrascu DL: Rome III: New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 15:237–241. 2006.PubMed/NCBI
12	Lewis SJ and Heaton KW: Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 32:920–924. 1997. View Article : Google Scholar : PubMed/NCBI
13	Endo Y, Yoshizawa M, Fukudo S, Sasaki M and Hongo M: Panic disorder in irritable bowel syndrome. Jpn J Psychosom Med. 40:339–346. 2000.
14	Liebregts T, Adam B, Bredack C, et al: Immune activation in patients with irritable bowel syndrome. Gastroenterology. 132:913–920. 2007. View Article : Google Scholar : PubMed/NCBI
15	Zung WW: A rating instrument for anxiety disorders. Psychosomatics. 12:371–379. 1971. View Article : Google Scholar : PubMed/NCBI
16	Zung WW: A self-rating depression scale. Arch Gen Psychiatry. 12:63–70. 1965. View Article : Google Scholar : PubMed/NCBI
17	Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG and Mayer EA: A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol. 100:115–123. 2005. View Article : Google Scholar : PubMed/NCBI
18	Ohman L and Simrén M: Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 7:163–173. 2010. View Article : Google Scholar : PubMed/NCBI
19	Nakamura M, Saito H, Kasanuki J, Tamura Y and Yoshida S: Cytokine production in patients with inflammatory bowel disease. Gut. 33:933–937. 1992. View Article : Google Scholar : PubMed/NCBI
20	Gecse K, Roka R, Ferrier L, et al: Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut. 57:591–599. 2008. View Article : Google Scholar : PubMed/NCBI
21	Bertiaux-Vandaele N, Youmba SB, Belmonte L, et al: The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype. Am J Gastroenterol. 106:2165–2173. 2011. View Article : Google Scholar : PubMed/NCBI
22	Dunlop SP, Hebden J, Campbell E, et al: Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol. 101:1288–1294. 2006. View Article : Google Scholar : PubMed/NCBI
23	Chadwick VS, Chen W, Shu D, et al: Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 122:1778–1783. 2002. View Article : Google Scholar : PubMed/NCBI
24	Woolf C, Allchorne A, Safieh-Garabedian B and Poole S: Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br J Pharmacol. 121:417–424. 1997. View Article : Google Scholar : PubMed/NCBI
25	Gao J: Correlation between anxiety-depression status and cytokines in diarrhea-predominant irritable bowel syndrome. Exp Ther Med. 6:93–96. 2013.PubMed/NCBI
26	Nicholl BI, Halder SL, Macfarlane GJ, et al: Psychosocial risk markers for new onset irritable bowel syndrome - results of a large prospective population-based study. Pain. 137:147–155. 2008. View Article : Google Scholar :
27	Qiu BS, Vallance BA, Blennerhassett PA and Collins SM: The role of CD4+ lymphocytes in the susceptibility of mice to stress-induced reactivation of experimental colitis. Nat Med. 5:1178–1182. 1999. View Article : Google Scholar : PubMed/NCBI
28	Kiliaan AJ, Saunders PR, Bijlsma PB, et al: Stress stimulates transepithelial macromolecular uptake in rat jejunum. Am J Physiol. 275(5 Pt 1): G1037–G1044. 1998.PubMed/NCBI